Shenzhen Shankang Pharmaceutical Technology Co., Ltd. is mainly engaged in the research and development, production, and sales of addiction treatment drugs represented by the treatment of opioid/new drug relapse and alcohol use disorders. It is an innovative drug research and development enterprise with international independent intellectual property rights and a global perspective, committed to creating a "Chinese solution" for addiction treatment.

      Since its establishment, the company has been committed to solving the global problem of addiction to psychoactive substances. Through years of research and development innovation accumulation, the company has formed an innovative research and development platform for drug delivery systems with long-acting slow-release implant technology as the core. It focuses on the innovative application of core technology in addiction treatment, central nervous system disease treatment, tumor treatment, infectious disease treatment and other disease treatment fields, and is committed to providing patients with safer, more effective and accessible treatment measures, and practicing social responsibility. The company will adhere to and continuously optimize its development strategy, continuously improve operational management efficiency and resource integration capabilities, strengthen innovative research and development, enrich its product line, and upgrade its domestic and international marketing system. Future Company is committed to building a first-class research and development center for slow-release drugs, creating an internationally leading innovative research and development platform for drug delivery systems, and industrializing research and development varieties to achieve sustainable development.